The 14 linked references in paper Z. Aisanov R., S. Avdeev N., V. Arkhipov V., A. Belevskiy S., I. Leshchenko V., S. Ovcharenko I., E. Shmelev I., A. Chuchalin G., З. Айсанов Р., С. Авдеев Н., В. Архипов В., А. Белевский С., И. Лещенко В., С. Овчаренко И., Е. Шмелев И., А. Чучалин Г. (2017) “Национальные клинические рекомендации по диагностике и лечению хронической обструктивной болезни легких: алгоритм принятия клинических решений // National clinical guidelines on diagnosis and treatment of chronic obstructive pulmonary disease: a clinical decision-making algorithm” / spz:neicon:pulmonology:y:2017:i:1:p:13-20

  1. Miravitlles M., Vogelmeier C., Roche N. et al. A review of national guidelines for management of COPD in Europe. Eur. Respir. J. 2016; 47 (2): 625–637. DOI: 10.1183/ 13993003.01170-2015.
  2. Eisner M.D., Anthonisen N., Coultas D. et al. An official American Thoracic Society public policy statement: novel risk factors and the global burden of chronic obstructive pulmonary disease.Am. J. Respir. Crit. Care Med. 2010; 182 (5): 693–718. DOI: 10.1164/rccm.200811-1757ST.
  3. Lamprecht B., McBurnie M.A., Vollmer W.M. et al. BOLD Collaborative Research Group: COPD in never smokers: results form the population-based burden of obstructive lung disease study. Chest. 2011; 139 (4): 752–763. DOI: 10.1378/chest.10-1253.
  4. Donaldson G.C., Seemungal T.A., Bhowmik A., Wedzicha J.A. Relationship between exacerbation frequency and lung function decline in chronic obstructive pulmonary disease. Thorax. 2002; 57 (10): 847–852. DOI: 10.1136/thorax.
  5. 10.847. 5. Kanner R.E., Anthonisen N.R., Connett J.E. Lower respiratory illnesses promote FEV1decline in current smokers but not ex-smokers with mild chronic obstructive pulmonary disease: results from the lung health study. Am. J. Respir. Crit. Care Med.2001; 164 (3): 358–364. DOI: 10.1164/ajrccm.164.3.2010017.
  6. Miravitlles M., D’Urzo A., Singh D., Koblizek V. Pharmacological strategies to reduce exacerbation risk in COPD: a narrative review. Respir. Res. 2016; 17 (1): 112. DOI: 10.1186/s12931-016-0425-5.
  7. Brusselle G.G., Gaga M. ERS guidelines, statements and technical standards published in the ERJ in 2014: a year in review. Eur. Respir. J. 2015; 45 (4): 863–866. DOI: 10.1183/09031936.00238514.
  8. Celli B.R., Decramer M., Wedzicha J.A. et al. An official American Thoracic Society/European Respiratory Society statement: research questions in COPD. Eur. Respir. J. 2015; 45 (4): 879–905. DOI: 10.1183/09031936.00009015.
  9. Hurst J., Vestbo J., Anzueto A. et al. Susceptibility to exacerbation in chronic obstructive pulmonary disease. N. Engl. J. Med.2010; 363: 1128–1138. DOI: 10.1056/NEJMoa 0909883.
  10. Российское респираторное общество. Хроническая обструктивная болезнь легких. Клинические рекомендации. Доступно на: http://www.spulmo.ru/obrazovatelnye( resursy/federalnye(klinicheskie(rekomendatsii
  11. Jones P.W., Brusselle G., Dal Negro R.W. et al. Patient-centered assessment of COPD in primary care: experience from a cross-sectional study of health-related quality of life in Europe. Prim. Care Respir. J. 2012; 21 (3): 329–336. DOI: 10.4104/pcrj.2012.00065.
  12. White P., Thorntoh H., Pinnock H. et al. Overtreatment of COPD with inhaled corticosteroids – implications for safety and costs: cross-sectional observational study. PLoS ONE.2013; 8: e75221. DOI: 10.1371/journal.pone.007 5221.
  13. Rossi A., Guerriero M., Corrado A. OPTIMO/AIPO Study Group. Withdrawal of inhaled corticosteroids can be safe in COPD patients at low risk of exacerbation: a real-life study on the appropriateness of treatment in moderate COPD patients (OPTIMO).Respir. Res.2014; 15: 77. DOI: 10.1186/ 1465-9921-15-77.
  14. Magnussen H., Disse B., Rodriguez-Roisin R. et al. Withdrawal of inhaled glucocorticoids and exacerbations of COPD. N. Engl. J. Med.2014; 371 (14): 1285–1294. DOI: 10.1056/NEJMoa1407154. Поступила 20.01.17